Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML).

Claudiani S, Metelli S, Kamvar R, Szydlo R, Khan A, Byrne J, Gallipoli P, Bulley SJ, Horne GA, Rothwell K, Copland M, Clark RE, Khorashad JS, Foroni L, Milojkovic D, Apperley JF.

Blood. 2019 Nov 13;134(Supplement_1):26. doi: 10.1182/blood-2019-131500.

PMID:
31724022
2.

Prolonged treatment free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations.

Claudiani S, Apperley JF, Khan A, Khorashad JS, Milojkovic D.

Haematologica. 2019 Sep 19. pii: haematol.2019.234179. doi: 10.3324/haematol.2019.234179. [Epub ahead of print]

3.

The influence of salivary amylase on total amylase elevation in CML patients treated with TKI therapy: a case series of 3 patients.

Nesr G, Claudiani S, Khorashad J, Apperley J, Milojkovic D.

Leuk Lymphoma. 2019 Jun 22:1-2. doi: 10.1080/10428194.2019.1627536. [Epub ahead of print] No abstract available.

PMID:
31232126
4.

Blast crisis of chronic myeloid leukemia with plasmacytoid dendritic cell phenotype associated with a rare fusion transcript, e13a3 BCR-ABL1.

Xu D, Claudiani S, Naresh K, Mucklow S, Neelakantan P, Yebra E, Apperley JF, Khorashad J, Milojkovic D.

Leuk Lymphoma. 2019 Jun 11:1-2. doi: 10.1080/10428194.2019.1622101. [Epub ahead of print] No abstract available.

PMID:
31184233
5.

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second generation tyrosine kinase inhibitors.

Nteliopoulos G, Bazeos A, Claudiani S, Gerrard G, Curry E, Szydlo R, Alikian M, Foong HE, Nikolakopoulou Z, Loaiza S, Khorashad JS, Milojkovic D, Perrotti D, Gale RP, Foroni L, Apperley JF.

Haematologica. 2019 May 9. pii: haematol.2018.200220. doi: 10.3324/haematol.2018.200220. [Epub ahead of print]

6.

T-cell prolymphocytic leukaemia in a patient with chronic myeloid leukaemia receiving nilotinib: first documented report.

Hanley B, Nesr G, Yebra-Fernandez E, Brown L, Rabitsch A, Killeen N, Claudiani S, Milojkovic D, Kanfer E, Apperley J, Naresh KN.

J Clin Pathol. 2019 Jul;72(7):511-512. doi: 10.1136/jclinpath-2019-205799. Epub 2019 Apr 19. No abstract available.

PMID:
31004076
7.

MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia.

Claudiani S, Gatenby A, Szydlo R, Nesr G, Abulafia AS, Palanicawandar R, Nteliopoulos G, Khorashad J, Foroni L, Apperley JF, Milojkovic D.

Haematologica. 2019 Nov;104(11):2206-2214. doi: 10.3324/haematol.2018.214809. Epub 2019 Mar 28.

8.

The argument for using imatinib in CML.

Claudiani S, Apperley JF.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):161-167. doi: 10.1182/asheducation-2018.1.161. Review.

PMID:
30504305
9.

Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.

García-Gutiérrez V, Milojkovic D, Hernandez-Boluda JC, Claudiani S, Martin Mateos ML, Casado-Montero LF, González G, Jimenez-Velasco A, Boque C, Martinez-Trillos A, Vázquez IM, Payer ÁR, Senín A, Amustio Díez E, García AB, Carrascosa GB, Ortí G, Ruiz BC, Fernández MÁ, Del Carmen García Garay M, Giraldo P, Guinea JM, De Las Heras Rodríguez N, Hernán N, Pérez AI, Piris-Villaespesa M, Lorenzo JLL, Martí-Tutusaus JMM, Vallansot RO, Ortega Rivas F, Puerta JM, Ramirez MJ, Romero E, Romo A, Rosell A, Saavedra SS, Sebrango A, Tallon J, Valencia S, Portero A, Steegmann JL; Grupo Español de Leucemia Mieloide Crónica (GELMC).

Ann Hematol. 2019 Feb;98(2):321-330. doi: 10.1007/s00277-018-3507-2. Epub 2018 Nov 16.

PMID:
30446802
10.

Development of artificial bone marrow fibre scaffolds to study resistance to anti-leukaemia agents.

Karimpoor M, IIlangakoon E, Reid AG, Claudiani S, Edirisinghe M, Khorashad JS.

Br J Haematol. 2018 Sep;182(6):924-927. doi: 10.1111/bjh.14883. Epub 2017 Aug 2. No abstract available.

PMID:
28771682
11.

E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy.

Claudiani S, Apperley JF, Gale RP, Clark R, Szydlo R, Deplano S, Palanicawandar R, Khorashad J, Foroni L, Milojkovic D.

Haematologica. 2017 Aug;102(8):e297-e299. doi: 10.3324/haematol.2017.168740. Epub 2017 May 11. No abstract available.

12.

Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia.

Claudiani S, Apperley JF, Deplano S, Khorashad J, Foroni L, Palanicawandar R, Perry R, Milojkovic D.

Am J Hematol. 2016 Nov;91(11):E480-E481. doi: 10.1002/ajh.24495. Epub 2016 Sep 3. No abstract available.

13.

Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis.

Claudiani S, Marktel S, Piemontese S, Assanelli A, Lupo-Stanghellini MT, Carrabba M, Guggiari E, Giglio F, De Freitas T, Marcatti M, Bernardi M, Corti C, Peccatori J, Lunghi F, Ciceri F.

Hematol Oncol. 2016 Sep;34(3):154-60. doi: 10.1002/hon.2183. Epub 2014 Dec 3.

PMID:
25469485

Supplemental Content

Loading ...
Support Center